Investigational drug · Phase 2
STP705
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Submental Fullness.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "STP705"
First trial start
2026
Jul 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STP705", any sponsor or status.
Conditions studied
As listed on its trial records.
- Submental Fullness
Largest trials
Live from ClinicalTrials.gov: studies naming "STP705" as an intervention, largest first.
- A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCCCompleted
SirnaomicsIndustry
NCT04844983 · 44 participants · Start May 18, 2021 · Primary completion Aug 24, 2022
Drug: STP705 · For: Squamous Cell Carcinoma in Situ
Sites: Scottsdale, Arizona; Aventura, Florida; West Palm Beach, Florida · 7 sites in all
SirnaomicsIndustry
NCT04669808 · 32 participants · Start Dec 28, 2020 · Primary completion Feb 9, 2023
Drug: STP705 · For: Basal Cell Carcinoma
Sites: Aventura, Florida
SirnaomicsIndustry
NCT07677683 · 30 participants (planned) · Start Jul 28, 2026 · Primary completion Jul 25, 2027
Drug: STP705 · For: Submental Fullness
Sites: Sydney, Australia
- A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid RecurrenceCompleted
SirnaomicsIndustry
NCT04844840 · 29 participants · Start Apr 29, 2021 · Primary completion May 17, 2023
Drug: STP705 · For: Keloid
Sites: Scottsdale, Arizona; Aventura, Florida; Hackensack, New Jersey
- Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCCCompleted
SirnaomicsIndustry
NCT04293679 · 25 participants · Start Mar 21, 2019 · Primary completion Oct 21, 2020
Drug: STP705 · For: Bowen's Disease; Cutaneous Squamous Cell Carcinoma in Situ
Sites: Aventura, Florida
SirnaomicsIndustry
NCT02956317 · 25 participants · Start Jan 2017 · Primary completion Jan 2018
Drug: STP705; Placebo · For: Hypertrophic Scar
Sites: Cypress, California
- Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCCTerminated
SirnaomicsIndustry
NCT05421013 · 9 participants · Start Aug 1, 2022 · Primary completion Mar 29, 2023
Drug: STP705 · For: Facial isSCC
Sites: Aventura, Florida
SirnaomicsIndustry
NCT05422378 · 8 participants · Start Aug 1, 2022 · Primary completion Feb 3, 2023
Drug: STP705 · For: Abdominal Obesity
Sites: Aventura, Florida
SirnaomicsIndustry
NCT04676633 · 5 participants · Start Mar 1, 2021 · Primary completion Jan 13, 2023
Drug: STP705 · For: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Sites: Scottsdale, Arizona; Los Angeles, California; Louisville, Kentucky · 4 sites in all
SirnaomicsIndustry
NCT05196373 · 0 participants · Start Dec 7, 2021 · Primary completion Jun 30, 2022
Drug: STP705 · For: Hypertrophic Scar
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF-β1 and COX-2 for Localized Fat Reduction II: Phase I Clinical Trial.
Nestor MS, Hetzel J, Awad N, et al. · J Cosmet Dermatol 2025
- Novel injectable polypeptide nanoparticle encapsulated siRNA targeting TGF-β1 and COX-2 for localized fat reduction I: Preclinical in vitro and animal models.
Nestor MS, Hetzel J, Awad N, et al. · J Cosmet Dermatol 2024
- Strategies for improving the safety and RNAi efficacy of noncovalent peptide/siRNA nanocomplexes.
Wang J, Chen G, Liu N, et al. · Adv Colloid Interface Sci 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.